Blueprint Medicines Corporation (BPMC)

86.85 -2.05 (-2.31%) At close: 04:00PM EDT

Blueprint Medicines Corporation

45 Sidney Street
Cambridge, MA 02139
United States
617 374 7580
https://www.blueprintmedicines.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 655

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Kathryn Haviland	President, CEO & Director	1.17M	N/A	1976
Mr. Alexis A. Borisy A.M.	Co-Founder & Director	50k	N/A	1972
Mr. Michael Landsittel	Chief Financial Officer	785.36k	N/A	1972
Ms. Christina Rossi	Chief Operating Officer	875.22k	N/A	1977
Ms. Tracey L. McCain Esq.	Executive VP, Chief Legal & Compliance Officer and Secretary	764.9k	N/A	1968
Dr. Fouad Namouni M.D.	President of Research & Development	916.4k	N/A	1969
Ms. Ariel Hurley	Senior VP, Finance & Principal Accounting Officer	N/A	N/A	1974
Dr. Christopher K. Murray Ph.D.	Senior VP of Technical Operations and Chief Technical Operations & Quality Officer	338.37k	N/A	1964
Dr. Percy H. Carter M.B.A., Ph.D.	Chief Scientific Officer	761.15k	N/A	1971
Jenna Cohen	Senior Director & Head of Investor Relations	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Blueprint Medicines Corporation’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.